Communiqués Milestone Pharmaceuticals Inc.

Actions

MIST

CA59935V1076

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:08:51 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,8130 ^USD	-0,33%		+0,61%	-60,73%

24/09	Milestone Pharmaceuticals recrute le premier participant canadien dans l’étude pivot de phase 3 ReVeRA-301 évaluant le spray nasal d’etripamil contre la fibrillation atriale avec fréquence ventriculaire rapide	CI
03/09	Milestone Pharmaceuticals reçoit l'approbation de la NMPA pour le spray nasal etripamil contre la TSVP en Chine	CI

Communiqués

24/09	Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR	AQ
03/09	Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States	AQ
02/09	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences	AQ
28/08	Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia on Patients Daily Lives and Quality of Life between Episodes	AQ
27/08	Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes	AQ
24/08	Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)	AQ
21/08	Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)	AQ
12/08	Milestone Pharmaceuticals: Q2 Earnings Snapshot	AQ
12/08	Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
04/08	Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026	AQ
06/07	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026	AQ
06/07	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
03/07	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
14/05	Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ	AQ
13/05	Milestone Pharmaceuticals: Q1 Earnings Snapshot	AQ
13/05	Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update	AQ
06/05	Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026	AQ
13/04	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST Nasal Spray in Patients with PSVT	AQ
13/04	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients with PSVT	AQ
10/04	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT	AQ
07/04	Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
02/04	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
31/03	Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies	AQ
20/03	Milestone Pharmaceuticals: Q4 Earnings Snapshot	AQ
20/03	Milestone Pharmaceuticals : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)	PU